X4 Pharmaceuticals (XFOR) Total Debt (2017 - 2025)

X4 Pharmaceuticals' Total Debt history runs 9 years deep, the most recent figure standing at $75.0 million for Q4 2025.

• Quarterly Total Debt fell 0.56% year-over-year to $75.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $75.0 million (down 0.56% YoY) and the FY2025 annual result came in at $75.0 million, down 0.56% from the prior year.
• Total Debt was $75.0 million for Q4 2025 at X4 Pharmaceuticals, down from $76.1 million in the prior quarter.
• Across five years, Total Debt topped out at $76.1 million in Q3 2025 and bottomed at $32.4 million in Q1 2023.
• A 5-year average of $52.2 million and a median of $50.7 million in 2022 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2023 — Total Debt retreated 20.69% — and 2024, when it surged 130.06%.
• X4 Pharmaceuticals' Total Debt stood at $33.3 million in 2021, then grew by 1.56% to $33.8 million in 2022, then jumped by 61.38% to $54.6 million in 2023, then soared by 38.22% to $75.4 million in 2024, then declined by 0.56% to $75.0 million in 2025.
• Business Quant data shows XFOR's Total Debt at $75.0 million in Q4 2025, $76.1 million in Q3 2025, and $75.0 million in Q2 2025.